Marez D, Sabbagh N, Legrand M, Lo-Guidice J M, Boone P, Broly F
Laboratoire de Biochimie et Biologie Moléculaire de l'Hôpital Calmette, Centre Hospitalier Régional et Universitaire de Lille, France.
Pharmacogenetics. 1995 Oct;5(5):305-11. doi: 10.1097/00008571-199510000-00006.
A novel loss-of function allele of the CYP2D6 gene was characterized in a PM individual using exon-by-exon PCR-SSCP analysis. This allele, we termed CYP2D6(F), harbours four mutations including a new mutation (D6-F) which abolishes the splice acceptor site of the 1st intron and results in a premature stop codon. DNA samples from a large population of healthy unrelated volunteers were tested for D6-F using a PCR-assay we developed for the specific identification of the mutation in genomic DNA. The prevalence of D6-F was very low. However, its identification combined with that of the previously reported gene inactivating mutations would further increase the phenotype prediction rate by genotyping.
利用逐外显子PCR-SSCP分析,在一名PM个体中鉴定出了CYP2D6基因一个新的功能缺失等位基因。我们将这个等位基因命名为CYP2D6(F),它含有四个突变,包括一个新突变(D6-F),该突变消除了第1内含子的剪接受体位点,导致提前出现终止密码子。使用我们开发的用于特异性鉴定基因组DNA中该突变的PCR检测方法,对大量健康无关志愿者的DNA样本进行了D6-F检测。D6-F的发生率非常低。然而,它与先前报道的基因失活突变的鉴定相结合,将通过基因分型进一步提高表型预测率。